Market Resilience: Aquestive Therapeutics Inc (AQST) Finishes Strong/Weak at 3.201, Down -2.14

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

Aquestive Therapeutics Inc (NASDAQ: AQST) closed the day trading at $3.20 down -2.14% from the previous closing price of $3.27. In other words, the price has decreased by -$2.14 from its previous closing price. On the day, 1.12 million shares were traded. AQST stock price reached its highest trading level at $3.27 during the session, while it also had its lowest trading level at $3.1745.

Ratios:

For a better understanding of AQST, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 6.28.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on May 10, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.

On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.

On March 28, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.Raymond James initiated its Outperform rating on March 28, 2024, with a $7 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Schobel Alexander Mark sold 50,000 shares for $6.00 per share. The transaction valued at 300,000 led to the insider holds 984,476 shares of the business.

Schobel Alexander Mark sold 25,000 shares of AQST for $129,685 on Mar 08 ’24. The Chief Innovation/Tech Officer now owns 1,040,371 shares after completing the transaction at $5.19 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 297696000 and an Enterprise Value of 257205056. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.66. Its current Enterprise Value per Revenue stands at 5.085 whereas that against EBITDA is -18.733.

Stock Price History:

The Beta on a monthly basis for AQST is 2.84, which has changed by 0.56097555 over the last 52 weeks, in comparison to a change of 0.26159418 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -23.95%, while the 200-Day Moving Average is calculated to be 24.95%.

Shares Statistics:

Over the past 3-months, AQST traded about 2.96M shares per day on average, while over the past 10 days, AQST traded about 1762560 shares per day. A total of 91.04M shares are outstanding, with a floating share count of 80.74M. Insiders hold about 11.31% of the company’s shares, while institutions hold 32.48% stake in the company. Shares short for AQST as of 1713139200 were 4008551 with a Short Ratio of 1.78, compared to 1710460800 on 2315549. Therefore, it implies a Short% of Shares Outstanding of 4008551 and a Short% of Float of 5.35.

Earnings Estimates

Aquestive Therapeutics Inc (AQST) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.14, while EPS last year was -$0.1. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.07 and low estimates of -$0.15.

Analysts are recommending an EPS of between -$0.27 and -$0.62 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.41, with 7.0 analysts recommending between -$0.24 and -$0.56.

Revenue Estimates

9 analysts predict $12.46M in revenue for the current quarter. It ranges from a high estimate of $13.08M to a low estimate of $11.7M. As of the current estimate, Aquestive Therapeutics Inc’s year-ago sales were $13.24MFor the next quarter, 9 analysts are estimating revenue of $12.6M. There is a high estimate of $13.3M for the next quarter, whereas the lowest estimate is $11.7M.

A total of 9 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $52.1M, while the lowest revenue estimate was $47.2M, resulting in an average revenue estimate of $50.02M. In the same quarter a year ago, actual revenue was $43.8MBased on 8 analysts’ estimates, the company’s revenue will be $58.76M in the next fiscal year. The high estimate is $77M and the low estimate is $49.8M.

Most Popular

[the_ad id="945"]